Skip to main content

Table 4 Association of loss of vascular access patencya with attribution of ESRD to SLE vs. other causes, among 2010 U.S. incident hemodialysis patients who started dialysis with a permanent vascular access

From: Comparison of vascular access outcomes in patients with end-stage renal disease attributed to systemic lupus erythematosus vs. other causes: a retrospective cohort study

Model No. (%) with access revision within 1 year Hazard ratio (95 % CI) for loss of patency, SLE-attributed vs. other ESRD
Unadjusted Adjusted for demographics Adjusted for demographics + clinical
All patients     
 SLE-attributed ESRD 21 (43.8 %) 0.70 (0.45-1.09) 0.81 (0.52-1.26) 0.88 (0.57-1.37)
 Other ESRD 7,169 (55.0 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.12 0.11 0.35 0.58
Among patients with AVFb     
 SLE-attributed ESRD 19 (44.2 %) 0.74 (0.46-1.17) 0.86 (0.54-1.37) 0.94 (0.59-1.50)
 Other ESRD 5,735 (52.9 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.26 0.20 0.53 0.80
Among patients with AVGb     
 SLE-attributed ESRD c 0.54 (0.13-2.15) 0.57 (0.14-2.30) 0.61 (0.15-2.47)
 Other ESRD 1,434 (65.8 %) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
P 0.35 0.38 0.43 0.49
  1. AVF arteriovenous fistula, AVG arteriovenous graft, ESRD end-stage renal disease, SLE systemic lupus eythematosus. Demographics: age (continuous), sex, race; clinical: body mass index (continuous), smoking, congestive heart failure, diabetes, and peripheral vascular disease
  2. aDefined as a revision or placement of a new AVF, AVG, or catheter (see Table 1)
  3. bN = 10,890 and 2,183 for AVF and AVG, respectively
  4. cNot reportable due to cell size < 10